Cellectar Biosciences and Nusano, a physics company transforming the production of radioisotopes, signed a multi-year supply agreement, the company announced recently.

According to a release, Nusano will provide Cellectar with iodine-125 (i-125) and actinium-225 (Ac-225) for its clinical trials and future commercial needs.

“Securing a reliable supply of both iodine-125 and actinium-225 is a critical milestone in advancing our targeted radiotherapy programs,” Cellectar CEO James Caruso said in a statement. “We look forward to partnering with Nusano to support our mutual vision to deliver new radiotherapeutics to patients in critical need of novel treatment options.

The clinical trials will focus on CLR-125 for triple-negative breast cancer.

Financial details of the partnership were not disclosed.